GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary
Genmab AS (NAS:GMAB)
[1]
Modestly Undervalued[5]$ 33.72
GF Score: 98/100Market Cap: $ 20,646 Mil
Industry: Healthcare - Biotechnology
IPO Date: 2010-10-05
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza... read more
Latest FY Operating Revenue by Business Segment
Business Segment Name2024Percentage
DARZALEX1,94264.68%
Kesimpta310.0110.32%
Net product sales243.188.10%
Milestone revenue139.524.65%
Reimbursement revenue138.964.63%
TEPEZZA102.823.42%
Other Segments126.404.21%
Financial Strength
Rank: 10 /10CurrentIndustry MedianHistorical Median
Cash-to-Debt24.026.4646.67
Equity-to-Asset0.820.670.90
Interest Coverage53.2590.115504.14
Piotroski F-Score635
Profitability Rank
Rank: 10 /10CurrentIndustry MedianHistorical Median
Operating Margin %36.76-99.7447.39
Net Margin %42.01-94.44543.53
ROE %27.63-40.05521.33
ROA %22.37-32.90519.32
ROC (Joel Greenblatt) %313.05-313.56225.96
Growth Rank(* per share data)
Rank: 10 /1010-Yr5-Yr1-Yr
Revenue Growth %38.328.716.9
EBITDA Growth %35.619.462.4
Oprt. Income Growth %33.215.331.9
EPS w/o NRI Growth %29.719.657.7
FCF Growth %55.232.917.4
Book Value Growth %32.120.717.5
Momentum Rank
Rank: 6 /10CurrentIndustry MedianHistorical Median
5-Day RSI80.7748.63N/A
9-Day RSI71.6647.24N/A
14-Day RSI67.0547.21N/A
6-1M Momentum %48.603.48N/A
12-1M Momentum %50.56-2.40N/A
Quarterly
Sep24Dec24Mar25Jun25Sep25
Revenue816.00805.24715.00925.001,022
Net Income186.00513.37195.00336.00401.00
EPS0.290.790.310.540.65
Revenue YoY %22.272.3518.5718.7425.25
Net Income YoY %-37.58296.901.5665.52115.59
EPS YoY %-35.40305.103.7473.16121.23
Free Cash Flow292.00319.77257.0052.00534.00
Cash & Equiv.2,5942,9443,2262,8993,411
Total Current Assets3,5503,8864,0373,9104,471
Short-Term Debt & CLO13.6312.8414.0016.0016.00
Total Current Liabilities686.75740.56756.00629.00741.00
Total Liabilities1,1591,2721,2901,1621,270
Stockholders Equity4,7815,1205,2965,3025,751
Warning Signs
SEVEREOperating Margin %: Declined
SEVEREAsset Growth: Faster than revenue growth
Good Signs
GOODFinancial Strength: Strong Financial Strength
GF Value Rank
Rank: 8 /10CurrentIndustry MedianHistorical Median
PE Ratio13.8128.32545.40
Forward P/E19.6622.685N/A
PB Ratio3.573.1257.97
PS Ratio5.7810.3518.28
P/FCF17.2535.159.94
Shiller P/E33.3636.375108.53
PEG Ratio0.821.7251.10
Valuation Analysis
Current% of Price
NCAV5.2516
Tangible Book5.9818
Graham Number16.8750
EPV19.0556
Peter Lynch Value27.6282
Price33.72
GF Value42.12125
DCF (FCF Based)69.97208
DCF (Earnings Based)75.68224
Median PS Value115.56343
Dividend & Ownership
Dividend Yield (TTM) %N/A
Dividend Yield (Forward) %N/A
Dividend Payout RatioN/A
Dividend Growth (5Y) %N/A
Yield on Cost (5Y) %N/A
Continuous Div. sinceN/A
Insider Ownership %N/A
Institution Ownership %10.07
As of 12-26-2025
* All financial numbers are in millions except for per share data, ratios and percentage change. "Neg. E" means negative equity.
20152016201720182019202020212022202320242025Performance
%GainSP500
1W6.343.13
1M9.413.54
3M14.504.74
6M62.5814.43
YTD61.5719.18
1Y64.7316.16
3Y-7.8123.28
5Y-2.9214.91
10Y9.6514.74
48.72
21.47
5.78
3M
1.3M
2015201620172018201920202021202220232024CurrentKey Data
13.9419.3723.4821.6824.1440.7648.7247.0643.2232.7733.89Highest Stock Price
5.789.7016.2912.1214.5317.1530.9226.8327.9420.0217.24Lowest Stock Price
7,9789,99110,12610,10214,49526,59725,99827,70420,80113,26120,646Market Cap
607.7617.7620.9620.5636.4658.9660.5660.1659.1646.3620.7Shares Outstanding-Diluted
72.7761.1657.1444.7843.1933.7458.6435.2332.1712.3813.81PE Ratio
15.6214.6210.028.236.888.427.697.064.432.593.57PB Ratio
49.0239.9826.6621.8017.4315.8820.6013.248.504.515.78PS Ratio
64.5057.1149.8334.7428.1623.2736.7622.9318.567.779.63EV-to-EBITDA
2015201620172018201920202021202220232024TTMPer Share Data
0.270.420.610.751.262.541.943.163.714.655.50Revenue per Share
0.180.270.290.360.511.190.681.190.981.692.29Earnings per Share
0.040.070.390.130.291.540.460.781.581.611.84Free Cash Flow per Share
----------------------Dividends per Share
0.811.091.621.893.144.755.085.987.164.795.93Tangible Book per Share
------13.9127.2259.0943.6778.1589.70103.83115.56Median PS Value
1.842.553.583.705.8911.837.9012.2813.2212.5316.29Graham Number
2015201620172018201920202021202220232024TTMIncome Statement
165.97256.98381.12463.40804.481,6711,2812,0882,4463,0033,467Revenue
165.97256.98381.12463.40804.481,6711,2812,0882,4122,8663,268Gross Profit
----------------98.6395.4294.25Gross Margin %
58.98108.01164.53252.00408.99627.75831.821,1861,6221,8891,985Total Operating Expense
106.99148.98216.59211.40395.491,043449.55902.00790.02977.041,283Operating Income
64.4657.9756.8345.6249.1662.4435.0843.2132.3032.5337.01Operating Margin %
111.84167.97177.91225.50324.73786.43450.16784.70646.151,0941,445Net Income
67.3965.3646.6848.6640.3747.0635.1337.5926.4236.4441.69Net Margin %
110.98159.96171.79246.94429.68977.50598.441,005847.331,2951,642EBIT
115.64165.75183.07260.42450.521,020636.191,057891.131,3531,707EBITDA
26.5428.1421.0120.1519.4829.8713.7721.4814.9922.3027.53ROE %
21.5125.5919.7119.1118.2127.2812.4319.4113.5018.8222.30ROA %
2015201620172018201920202021202220232024Sep25Balance Sheet
511.69554.96873.87935.381,6452,6582,9443,2134,1772,9443,411Cash & Equivalents & MS
537.27693.02976.481,1392,0933,1063,4614,0614,9203,8864,471Total Current Assets
571.65741.211,0641,2962,2703,4953,7494,3355,2396,3917,021Total Assets
0.02------3.906.949.4410.6513.3612.8416.00Short-Term Debt & CLO
60.7058.2352.7268.02140.63207.10238.71262.38368.80740.56741.00Total Current Liabilities
--------23.2445.7855.2675.28100.96130.73126.00Long-Term Debt & CLO
60.9158.2353.3068.48164.31334.21370.09408.33546.231,2721,270Total Liabilities
510.74682.981,0111,2282,1063,1603,3793,9274,6935,1205,751Total Stockholders Equity
510.74682.981,0111,2282,1063,1603,3793,9274,6935,1205,751Total Equity
2015201620172018201920202021202220232024TTMCashflow Statement
45.6246.37256.07155.49198.801,063339.18563.051,0961,0841,232Cash Flow from Operations
-70.44-143.56-107.65-272.37-297.30-388.59-146.30-397.39-190.34-1,3825.81Cash Flow from Investing
94.2012.9034.65-10.88548.7111.74-63.94-113.56-89.97-546.77-422.77Cash Flow from Financing
75.42-80.23167.76-124.85452.61612.88258.35134.72738.50-698.84934.16Net Change in Cash
128.0243.44217.2381.65532.521,2001,3641,4242,2071,3751,761Ending Cash Position
-19.83-4.69-14.34-73.23-16.64-50.74-38.36-45.63-55.83-42.41-69.41Capital Expenditure
25.7941.69241.7382.26182.161,013300.82517.421,0401,0421,163Free Cash Flow
Competitor(* Up to 5 competitors are listed here. See full competitors list in the Competitive Comparison section below)
TickerCompanyMarket Cap
($M)
PE RatioGF Score
/100
Financial
Strength /10
Profitability
Rank /10
GF Value
Rank /10
Growth
Rank /10
Momentum
Rank /10
NAS:BNTXBioNTech SE22,851At Loss7284745
NAS:GMABGenmab AS20,64613.819810108106
NAS:INCYIncyte Corp19,71916.8290108786
HKSE:01801Innovent Biologics Inc17,876110.928183799
XKRX:196170Alteogen Inc16,025212.2486946109
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Strength[2] (Quarterly data, as of Sep. 2025) : Good (10/10)


Cash-to-Debt : 24.02

Cash-to-Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. A high ratio indicates that a company is better able to pay back its debt, and is thus able to take on more debt if necessary.


Equity-to-Asset : 0.82

Equity-to-Asset ratio is calculated as total stockholders equity divided by its total assets. Equity-to-Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity-to-Asset ratio (more leveraged) may have higher ROE % because of the leverage.


Debt-to-Equity : 0.03

A high Debt-to-Equity ratio generally means that a company has been aggressive in financing its growth with debt.


Piotroski F-Score : 6

The Piotroski F-Score is used to determine the strength of a firm's financial position, with 9 being the best and 0 being the worst.

0
1
2
3
4
5
6
7
8
9


WACC : 3.95% vs ROIC : 41.09%

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business.


Dividend Yield : 0.00%

Dividend yield is a way to measure how much cash flow you are getting for each dollar invested in an equity position.

GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Profitability[3] (Annual data, as of Dec. 2024) : Good (10/10)


Revenue : $1,022 Mil vs Net Income : $401 Mil

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Net Income is a company's total profit. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.


Cash & Equivalents : $1,761 Mil vs Long-Term Debt* : $126 Mil

Cash & equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash. Long-Term Debt* consists of loans and obligations lasting over one year.


Operating Margin % : 44.91%

Operating margin % measures how much profit a company makes on a dollar of sales. Operating Margin % is calculated as Operating Income divided by Revenue.


EPS without NRI : $0.65

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.


Dividends per Share : $0.00

Dividends per Share is the amount of dividends that the shareholders of a company receive on a per-share basis. It is calculated using the total dividends paid out to shareholders over one fiscal year and the number of shares outstanding.


Free Cash Flow per Share : $0.86

Free Cash flow per Share is the amount of Free cash flow per outstanding share of the company's stock.

GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Valuation (Quarterly data, as of Sep. 2025)

These valuation metrics should give you a sense of reasonable prices, but be careful with them. Always seek to understand why a valuation is changing over time.


Valuation Chart (Current stock price : $33.72)


PE Ratio without NRI : 14.49

The price-to-earnings ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.


PB Ratio : 3.28

The price-to-book ratio measures the valuation of the stock relative to the underlying asset of the company.


PS Ratio : 5.25

The price-to-sales ratio is a valuation ratio that compares a company’s stock price to its revenues. The price-to-sales ratio is an indicator of the value placed on each dollar of a company’s sales or revenues.


Price-to-Free-Cash-Flow : 15.66

Price-to-free-cash-flow is very similar to the valuation metric of price-to-operating-cash-flow but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.


EV-to-EBIT : 8.91

Enterprise value of a company divided by its trailing 12 months earnings before interest and taxes (EBIT).

GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Valuation Bands

In these charts the 10-year valuation bands of the price-to-earnings ratio (PE Ratio), price-to-book ratio (PB Ratio), price-to-sales ratio (PS Ratio) and price-to-operating-cash-flow ratio (POCF) are drawn together with the historical stock prices. For example, the upper line of the PE band is where the stock price would have been if it were always traded at the maximum PE ratio of the past 10 years. The lower line of the PE band is where the stock price would have been if it were always traded at the lowest PE ratio of the past 10 years. It is always better if the stock price is close to the lower line, which indicates a lower valuation.


Historical Price and PE Band


Historical Price and PS Band


Historical Price and PB Band


Historical Price and Price-to-Operating-Cash-Flow (POCF) Band

GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Warning Signs

GuruFocus conducted a thorough checkup using a checklist of 32 items that cover the areas of financial strength, profitability, growth, and valuation of each company. The purpose of Warning Signs is to warn you that the company may have red flags in certain areas, helping to avoid overlooking them. These warning signs do not necessarily mean you should not invest in the stock. But you should be aware of them before you invest.


Severe Warning Signs

Operating Margin % : Declined

Genmab AS operating margin has been in a 5-year decline. The average rate of decline per year is -10.4%.

Asset Growth : Faster than revenue growth

If a company builds assets at 34.1% a year, faster than its revenue growth rate of 28.7% over the past 5 years, it means that the company may be getting less efficient.

Good Signs

Financial Strength : Strong Financial Strength

Genmab AS shows strong financial strength.

Altman Z-Score : Strong

Altman Z-score of 12.49 is strong.

Beneish M-Score : Unlikely manipulator

Beneish M-Score -2.47 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

Interest Coverage : Comfortable

Ben Graham prefers companies' interest coverage to be at least 5. Genmab AS has enough cash to cover all of its debt. Its financial situation is stable.

Revenue per Share : Consistent growth

Genmab AS has shown predictable revenue and earnings growth.

Medium Warning Signs

Price : Close to 2-year high

Genmab AS stock Price is close to 2-year high.

PB Ratio : Close to 1-year high

Genmab AS stock PB Ratio (=3.57) is close to 1-year high of 3.57.

PS Ratio : Close to 1-year high

Genmab AS stock PS Ratio (=5.78) is close to 1-year high of 5.78.

Valuation : Forward PE Ratio

Company's forward PE ratio is higher than the trailing PE ratio. Company's earnings are in decline.
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Competitive Comparison


5 Year Price Change Comparison



Financial Strength

CompanyFinancial StrengthCash-to-DebtEquity-to-AssetDebt-to-EquityInterest CoveragePiotroski F-ScoreAltman Z-ScoreBeneish M-ScoreWACC %ROIC %
OCSE:BAVABavarian Nordic AS10/1022.220.870.01102.1576.97-2.591.5021.78
NAS:GMABGenmab AS10/1024.020.820.0353.25612.49-2.473.9541.09
NAS:INCYIncyte Corp10/1071.000.740.01554.6179.17-2.5610.2632.02
OCSE:ZEALZealand Pharma AS10/1039.780.900.03233.80815.57101.229.421090.51
XBRU:ARGXargenx SE10/1091.030.850.01198.23329.90-0.242.3038.67
OCSE:ALK BAlk-Abello AS9/101.440.730.0850.76715.77-2.445.4017.71
OCSE:GUBRAGubra AS9/1029.370.420.0817.02533.36-3.089.47882.47
NAS:REGNRegeneron Pharmaceuticals Inc9/103.120.770.0990.4457.77-2.606.9112.86
NAS:ONCBeOne Medicines Ltd8/103.960.540.25N/A85.84-2.531.992.21
NAS:BNTXBioNTech SE8/1059.160.870.010.0046.11-2.438.81-2.23
HKSE:01801Innovent Biologics Inc8/102.820.610.2320.6468.93-2.1310.3113.09
XKRX:207940Samsung BioLogics Co Ltd8/101.600.660.1038.0879.15-2.705.9010.49
NAS:VRTXVertex Pharmaceuticals Inc8/103.430.700.110.00711.40-3.127.83-0.56
OCSE:STRAPStrategic Partners A/S7/10No Debt0.960.000.0030.000.00-1.23-92.26
XBRU:UCBUCB SA7/100.700.560.3010.5095.04-2.386.158.58
NAS:ALNYAlnylam Pharmaceuticals Inc6/102.080.055.591.6366.16-1.2010.200.00
XKRX:068270Celltrion Inc6/100.330.790.1711.7876.32-2.345.243.79
NAS:INSMInsmed Inc6/102.920.400.610.00312.32-2.4014.64-193.88
ASX:CSLCSL Ltd5/100.190.490.606.5783.43-2.467.026.55
OCSE:PEGPharma Equity Group AS0/100.040.630.470.0030.000.006.19-27.19
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Competitive Comparison - Cont.


Profitability

CompanyProfitability RankOperating
Margin %
Net Margin %ROE %ROA %Price-to-Free-Cash-FlowROC (Joel Greenblatt) %3-Year Revenue Growth %3-Year EBITDA Growth %3-Year EPS w/o NRI Growth %
ASX:CSLCSL Ltd10/1018.7917.9614.176.7236.7125.6915.3015.6011.50
XKRX:068270Celltrion Inc10/1022.5118.944.363.5579.8321.8911.60-6.30-18.40
NAS:GMABGenmab AS10/1036.7642.0127.6322.3717.25313.0537.4033.0042.40
NAS:REGNRegeneron Pharmaceuticals Inc9/1026.7232.1315.3711.9822.1850.22-4.90-18.80-15.10
XKRX:207940Samsung BioLogics Co Ltd9/1036.6428.9914.119.18108.3435.4439.7037.0038.60
NAS:INCYIncyte Corp8/1026.1024.7031.1020.9617.34195.7914.40-11.90-26.90
XBRU:UCBUCB SA8/1018.2519.4513.947.9739.4698.462.107.10-13.50
NAS:VRTXVertex Pharmaceuticals Inc8/10-0.7931.3522.1315.7735.84166.0913.60-44.80-68.20
OCSE:ALK BAlk-Abello AS7/1024.2218.1219.5513.65240.5939.5112.1036.7054.90
OCSE:BAVABavarian Nordic AS6/1036.2135.5020.7717.2211.7167.9934.50150.600.00
NAS:ALNYAlnylam Pharmaceuticals Inc4/108.251.3631.150.99256.8518.7335.2035.5042.30
NAS:BNTXBioNTech SE4/10-4.55-18.64-3.13-2.710.001.53-47.400.000.00
NAS:ONCBeOne Medicines Ltd3/103.671.381.891.0976.9510.2441.9036.9027.00
HKSE:01801Innovent Biologics Inc3/1016.499.968.555.22212.5023.8019.800.0061.00
XBRU:ARGXargenx SE3/1021.8143.5329.0225.340.00126.9255.000.000.00
OCSE:GUBRAGubra AS2/1083.4766.22246.03126.763.732226.251.400.000.00
NAS:INSMInsmed Inc2/10-221.53-264.83-193.23-55.210.00-954.929.70-13.40-13.40
OCSE:ZEALZealand Pharma AS2/1077.2771.4757.8252.574.715419.25-28.002.501.30
OCSE:STRAPStrategic Partners A/S1/100.000.00-17.87-15.720.000.000.0085.7086.30
OCSE:PEGPharma Equity Group AS0/100.000.00-55.23-30.820.00-6781.200.000.000.00

Valuation

CompanyPE RatioPB RatioPS RatioPrice-to-Intrinsic-Value-Projected-FCFPrice-to-Intrinsic-Value-DCF (Earnings Based)Price-to-Median-PS-ValuePrice-to-Peter-Lynch-Fair-ValuePrice-to-Graham-NumberEarnings Yield (Joel Greenblatt) %Forward Rate of Return (Yacktman) %
NAS:BNTXBioNTech SEAt Loss1.056.430.370.000.000.000.000.340.00
NAS:INSMInsmed IncAt Loss39.8975.980.000.000.000.000.00-3.000.00
OCSE:PEGPharma Equity Group ASAt Loss2.930.000.000.000.000.000.00-13.690.00
OCSE:STRAPStrategic Partners A/SAt Loss1.560.000.000.000.000.000.00-24.940.00
OCSE:GUBRAGubra AS4.886.953.220.000.000.000.001.2440.050.00
OCSE:ZEALZealand Pharma AS5.312.243.782.050.000.000.000.7339.220.00
OCSE:BAVABavarian Nordic AS6.171.132.2111.510.000.340.000.7521.230.00
NAS:GMABGenmab AS13.813.575.781.240.450.291.222.009.9917.22
NAS:INCYIncyte Corp16.824.244.201.970.000.560.001.769.450.00
NAS:REGNRegeneron Pharmaceuticals Inc18.772.676.051.170.560.840.001.466.772.01
ASX:CSLCSL Ltd21.012.803.771.601.340.421.687.535.6613.60
NAS:VRTXVertex Pharmaceuticals Inc32.656.7910.202.480.000.840.002.973.95-10.95
XBRU:ARGXargenx SE33.618.3214.700.000.000.400.003.992.080.00
XBRU:UCBUCB SA35.104.726.833.020.003.870.009.443.74-3.63
OCSE:ALK BAlk-Abello AS45.708.178.276.020.001.501.834.832.9920.50
XKRX:207940Samsung BioLogics Co Ltd49.056.4314.225.610.000.001.924.962.7120.38
XKRX:068270Celltrion Inc51.952.3810.142.582.300.550.005.372.33-2.36
HKSE:01801Innovent Biologics Inc110.928.4710.890.000.000.000.007.421.070.00
NAS:ONCBeOne Medicines Ltd799.318.356.990.000.000.000.005.080.560.00
NAS:ALNYAlnylam Pharmaceuticals Inc1669.54225.7416.560.000.000.390.0042.810.250.00
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Peter Lynch Chart[4]

GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Per Share Data


Per Share Data

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
0.25
0.23
0.14
0.19
0.24
0.24
0.27
0.42
0.61
0.75
1.26
2.54
1.94
3.16
3.71
4.65
5.50
Revenue per Share
-0.03
-0.03
-0.08
-0.04
0.03
0.09
0.19
0.27
0.30
0.42
0.71
1.55
0.96
1.60
1.35
2.09
2.71
EBITDA per Share
-0.07
-0.03
-0.08
-0.04
0.03
0.09
0.18
0.26
0.28
0.40
0.68
1.48
0.91
1.52
1.29
2.00
2.60
EBIT per Share
-0.43
-0.13
-0.23
-0.19
0.04
0.09
0.18
0.27
0.29
0.36
0.51
1.19
0.68
1.19
0.98
1.69
2.29
Earnings per Share (Diluted)
-0.15
-0.06
-0.09
-0.04
0.03
0.09
0.19
0.26
0.35
0.32
0.49
1.31
0.55
1.12
1.08
1.46
1.99
EPS without NRI
--
--
--
-0.12
-0.05
0.02
0.04
0.06
0.36
0.17
0.18
1.43
0.45
0.80
1.28
1.53
2.51
Owner Earnings per Share (TTM)
-0.25
0.10
-0.17
0.02
-0.05
0.02
0.04
0.07
0.39
0.13
0.29
1.54
0.46
0.78
1.58
1.61
1.84
Free Cash Flow per Share
-0.24
0.11
-0.17
0.03
-0.05
0.04
0.08
0.08
0.41
0.25
0.31
1.61
0.51
0.85
1.66
1.68
1.95
Operating Cash Flow per Share
0.55
0.66
0.43
0.53
0.56
0.76
0.86
0.92
1.43
1.53
2.53
4.06
4.48
4.92
6.39
4.63
5.54
Cash per Share
0.56
0.43
0.19
0.14
0.24
0.58
0.86
1.13
1.66
2.00
3.25
4.83
5.14
6.01
7.18
8.06
9.34
Book Value per Share
0.56
0.43
0.19
0.14
0.24
0.57
0.81
1.09
1.62
1.89
3.14
4.75
5.08
5.98
7.16
4.79
5.93
Tangible Book per Share
0.01
0.05
0.01
0.00
0.00
--
--
--
--
--
0.04
0.08
0.10
0.13
0.18
0.23
0.23
Total Debt per Share
--
1.35
0.65
1.40
3.91
5.86
13.40
16.58
16.58
16.48
22.33
40.66
39.56
42.38
31.84
20.87
33.72
Month End Stock Price
449
449
449
460
519
573
608
618
621
620
636
659
660
660
659
646
621
Shares Outstanding (Diluted Average)

Ratios

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
-59.07
-25.92
-75.00
-113
21.89
21.67
26.54
28.14
21.01
20.15
19.48
29.87
13.77
21.48
14.99
22.30
27.53
ROE %
--
-8.23
-21.68
-10.90
1.32
2.16
1.70
1.92
2.10
2.45
2.83
3.55
1.79
3.04
3.38
8.61
7.74
ROE % Adjusted to Book Value
-37.54
-13.18
-29.08
-30.13
6.70
12.48
21.51
25.59
19.71
19.11
18.21
27.28
12.43
19.41
13.50
18.82
22.30
ROA %
-64.85
-25.92
-75.00
-113
21.95
22.19
27.81
29.47
21.59
21.01
20.35
30.60
13.97
21.66
15.06
28.34
45.83
Return-on-Tangible-Equity
-39.79
-13.18
-29.08
-30.13
6.71
12.65
22.34
26.69
20.22
19.88
18.97
27.89
12.59
19.56
13.55
22.94
32.97
Return-on-Tangible-Asset
-31.88
-156
-556
-385
289
1,173
2,638
361
240
226
161
278
157
169
122
237
312
ROC (Joel Greenblatt) %
-9.30
-6.41
-23.48
-20.47
10.48
19.17
25.46
26.80
20.28
22.05
25.59
36.09
17.61
26.51
18.95
24.62
28.46
ROCE %
--
--
--
--
-49.78
-50.12
-372
117
28.11
23.28
20.12
34.15
13.40
21.82
10.55
9.35
24.64
5-Year RORE %
--
73.98
19.20
52.36
-64.35
-80.92
-444
50.11
-159
-1.27
57.77
434
1,335
135
85.13
7.74
693
1-Year ROIIC %
-31.94
-13.65
-21.58
-11.08
7.09
32.64
116
124
134
84.94
76.67
146
54.58
97.34
76.88
48.70
41.30
ROIC %
17.63
9.67
7.22
5.57
5.98
3.15
7.07
7.95
8.15
4.79
4.95
8.32
9.63
10.55
9.25
2.77
3.95
WACC %
924
49.36
2.74
31.40
84.21
256
45.33
176
--
--
3.87
4.14
3.37
7.45
10.38
12.98
16.39
Effective Interest Rate on Debt %
--
-0.08
-51.74
--
--
--
--
--
--
--
--
--
--
--
98.63
95.42
94.25
Gross Margin %
-84.98
-27.61
-71.07
-24.08
10.44
31.18
64.46
57.97
56.83
45.62
49.16
62.44
35.08
43.21
32.30
32.53
37.01
Operating Margin %
-172
-55.23
-170
-101
16.93
35.43
67.39
65.36
46.68
48.66
40.37
47.06
35.13
37.59
26.42
36.44
41.69
Net Margin %
-13.16
-10.61
-54.92
-19.86
12.12
36.89
69.68
64.50
48.03
56.20
56.00
61.05
49.65
50.64
36.43
45.05
49.23
EBITDA Margin %
-97.27
46.07
-125
14.63
-19.29
15.60
27.49
18.04
67.19
33.55
24.71
63.62
26.47
26.97
44.80
36.10
-- OCF Margin %
-100
44.33
-127
12.78
-20.85
6.73
15.54
16.22
63.42
17.75
22.64
60.59
23.48
24.78
42.52
34.69
33.54
FCF Margin %
0.02
0.12
0.02
0.02
0.00
--
--
--
--
--
0.01
0.02
0.02
0.02
0.02
0.03
0.03
Debt-to-Equity
0.58
0.44
0.31
0.23
0.38
0.71
0.89
0.92
0.95
0.95
0.93
0.90
0.90
0.91
0.90
0.80
0.82
Equity-to-Asset
0.01
0.05
0.01
0.00
0.00
--
--
--
--
--
0.01
0.02
0.02
0.02
0.02
0.02
0.02
Debt-to-Asset
0.42
0.57
0.69
0.77
0.62
0.29
0.11
0.08
0.05
0.05
0.07
0.10
0.10
0.09
0.10
0.20
0.18
Liabilities-to-Assets
21.76
-0.02
-8.86
29.98
39.59
35.22
31.93
39.15
42.22
39.27
45.11
57.98
35.38
51.65
50.39
49.28
50.42
Gross-Profit-to-Asset %
--
1.26
0.46
0.54
0.80
0.51
0.79
1.06
-0.20
5.84
0.39
0.86
1.05
1.35
1.07
1.38
1.76
Degree of Financial Leverage
0.22
0.24
0.17
0.30
0.40
0.35
0.32
0.39
0.42
0.39
0.45
0.58
0.35
0.52
0.51
0.52
0.54
Asset Turnover
81.12
55.63
71.81
77.88
73.40
55.80
47.13
116
111
117
148
93.41
131
117
116
101
99.11
Days Sales Outstanding
--
25.42
22.95
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Days Payable
--
--
--
--
--
--
--
--
--
--
--
--
--
--
92.06
22.73
21.34
Days Inventory
81.12
30.21
48.86
77.88
73.40
55.80
47.13
116
111
117
148
93.41
131
117
208
123
120
Cash Conversion Cycle
4.50
6.56
5.08
4.69
4.97
6.54
7.74
3.14
3.29
3.12
2.47
3.91
2.79
3.13
3.14
3.63
3.68
Receivables Turnover
--
--
--
--
--
--
--
--
--
--
--
--
--
--
3.96
16.06
17.11
Inventory Turnover
--
1.00
1.52
--
--
--
--
--
--
--
--
--
--
--
0.01
0.05
0.06
COGS-to-Revenue
0.06
--
--
--
--
--
--
--
--
--
--
--
--
--
0.00
0.00
0.00
Inventory-to-Revenue
0.03
0.02
0.02
0.02
0.02
0.09
0.12
0.02
0.04
0.16
0.02
0.03
0.03
0.02
0.02
0.01
0.02
Capex-to-Revenue
--
--
--
--
0.15
0.28
0.19
0.03
0.07
0.35
0.04
0.05
0.09
0.05
0.07
0.04
0.05
Capex-to-Operating-Income
--
0.04
--
0.13
--
0.57
0.44
0.10
0.06
0.47
0.08
0.05
0.11
0.08
0.05
0.04
0.06
Capex-to-Operating-Cash-Flow
* All financial numbers are in millions except for per share data, ratios and percentage change. When Return-on-Tangible-Equity displays Neg. E, it means the the tangible equity is negative. When ROE % or ROE % Adjusted to Book Value displays Neg. E, it means the the total shareholders equity is negative.
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Statement

Income Statement

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
113
104
61.25
85.90
123
139
166
257
381
463
804
1,671
1,281
2,088
2,446
3,003
3,467
Revenue
--
104
92.94
--
--
--
--
--
--
--
--
--
--
--
33.56
137
199
Cost of Goods Sold
113
-0.08
-31.69
85.90
123
139
166
257
381
463
804
1,671
1,281
2,088
2,412
2,866
3,268
Gross Profit
--
-0.08
-51.74
--
--
--
--
--
--
--
--
--
--
--
98.63
95.42
94.25
Gross Margin %
28.64
28.59
11.84
11.45
12.35
12.99
13.36
14.49
23.69
32.78
51.27
109
195
385
490
529
577
Selling, General, & Admin. Expense
180
--
92.94
95.13
97.65
82.56
71.43
93.51
141
219
358
518
636
801
1,133
1,360
1,408
Research & Development
0.00
-0.00
-92.94
-0.00
-0.00
0.00
-25.81
--
-0.00
-0.00
-0.00
-0.00
-0.00
0.00
-0.00
--
-0.00
Other Operating Expense
209
28.59
11.84
107
110
95.55
58.98
108
165
252
409
628
832
1,186
1,622
1,889
1,985
Total Operating Expense
-95.90
-28.67
-43.53
-20.68
12.82
43.30
107
149
217
211
395
1,043
450
902
790
977
1,283
Operating Income
-84.98
-27.61
-71.07
-24.08
10.44
31.18
64.46
57.97
56.83
45.62
49.16
62.44
35.08
43.21
32.30
32.53
37.01
Operating Margin %
4.82
0.25
3.88
3.16
5.30
6.26
5.46
4.61
6.61
9.65
17.99
30.41
29.99
46.63
144
139
117
  Interest Income
-34.87
-7.07
-0.36
-0.48
-0.62
-0.66
-0.02
-0.03
-0.32
--
-1.05
-1.65
-1.98
-5.61
-10.39
-16.74
-23.74
  Interest Expense
-30.05
-6.82
3.52
2.68
4.68
5.60
5.44
4.58
6.29
9.65
16.94
28.76
28.01
41.02
134
122
93.08
Net Interest Income
60.09
13.65
3.39
-2.22
-5.39
-0.34
-1.46
6.37
-51.41
25.89
16.19
-96.36
119
56.56
-86.86
179
242
Other Income (Expense)
-65.85
-21.84
-36.62
-20.22
12.11
48.55
111
160
171
247
429
976
596
1,000
837
1,279
1,619
Pre-Tax Income
-1.14
-3.72
-1.03
0.47
0.88
0.65
0.88
8.05
6.45
-21.45
-104
-189
-146
-215
-191
-184
-173
Tax Provision
-1.73
-17.05
-2.82
2.31
-7.27
-1.33
-0.79
-5.03
-3.76
8.69
24.24
19.41
24.53
21.50
22.80
14.40
10.70
Tax Rate %
-128
-31.78
-66.43
-66.58
7.81
-0.00
-0.00
0.00
--
0.00
--
-0.00
-0.00
--
-0.00
--
-- Other Net Income (Loss)
-195
-57.34
-104
-86.34
20.80
49.19
112
168
178
225
325
786
450
785
646
1,094
1,445
Net Income Including Noncontrolling Interests
-66.99
-25.57
-37.66
-19.75
12.99
49.19
112
168
178
225
325
786
450
785
646
1,094
1,445
  Net Income (Continuing Operations)
-128
-31.78
-66.43
-66.58
7.81
--
--
--
--
--
--
--
--
--
--
--
--   Net Income (Discontinued Operations)
-195
-57.34
-104
-86.34
20.80
49.19
112
168
178
225
325
786
450
785
646
1,094
1,445
Net Income
-172
-55.23
-170
-101
16.93
35.43
67.39
65.36
46.68
48.66
40.37
47.06
35.13
37.59
26.42
36.44
41.69
Net Margin %
-0.43
-0.13
-0.23
-0.19
0.04
0.09
0.19
0.28
0.29
0.37
0.52
1.21
0.69
1.20
0.99
1.71
2.30
EPS (Basic)
-0.43
-0.13
-0.23
-0.19
0.04
0.09
0.18
0.27
0.29
0.36
0.51
1.19
0.68
1.19
0.98
1.69
2.29
EPS (Diluted)
449
449
449
460
519
573
608
618
621
620
636
659
660
660
659
646
621
Shares Outstanding (Diluted Average)
-30.98
-14.77
-36.27
-19.74
12.72
49.21
111
160
172
247
430
977
598
1,005
847
1,295
1,642
EBIT
16.13
3.75
2.63
2.68
2.16
2.01
4.66
5.80
11.28
13.48
20.84
42.81
37.76
52.10
43.80
57.62
64.62
Depreciation, Depletion and Amortization
-14.85
-11.02
-33.64
-17.06
14.88
51.22
116
166
183
260
451
1,020
636
1,057
891
1,353
1,707
EBITDA
-13.16
-10.61
-54.92
-19.86
12.12
36.89
69.68
64.50
48.03
56.20
56.00
61.05
49.65
50.64
36.43
45.05
49.23
EBITDA Margin %
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Statement

Cashflow Statement

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
-193
-53.62
-103
-86.80
19.92
48.55
111
160
171
247
429
976
596
1,000
837
1,279
1,619
Net Income From Continuing Operations
16.13
3.75
2.63
2.68
2.16
2.01
4.66
5.80
11.28
13.48
20.84
42.81
37.76
52.10
43.80
57.62
64.62
Depreciation, Depletion and Amortization
9.94
--
-0.15
-8.34
-0.17
6.83
-13.18
-112
43.51
-118
-249
50.58
-154
-306
118
-222
-153
  Change In Receivables
13.30
6.30
-0.26
--
--
--
--
--
--
--
--
--
--
--
-8.46
-0.70
-3.70
  Change In Inventory
-0.57
-0.22
0.11
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Change In Prepaid Assets
--
--
4.41
3.68
6.38
0.74
-0.69
-1.33
7.57
20.53
65.97
27.77
46.28
40.73
92.35
120
140
  Change In Payables And Accrued Expense
-38.33
61.43
-39.54
35.76
-50.67
-43.77
-65.00
-7.72
-12.41
0.00
-0.00
84.79
--
0.00
--
0.00
--   Change In Other Working Capital
-15.65
67.50
-35.44
31.10
-44.45
-36.21
-78.87
-122
38.68
-97.12
-183
163
-107
-265
202
-103
-16.96
Change In Working Capital
--
--
3.50
2.13
2.14
4.53
5.36
7.53
12.25
13.94
22.04
33.06
47.19
63.19
87.01
101
115
Stock Based Compensation
--
--
59.74
58.65
--
--
--
--
--
--
--
--
--
--
--
16.04
6.04
Asset Impairment Charge
83.23
30.20
-3.69
4.81
-3.46
2.78
3.51
-5.34
22.40
-21.75
-90.10
-152
-235
-287
-74.24
-266
-555
Cash Flow from Others
-110
47.84
-76.31
12.57
-23.69
21.66
45.62
46.37
256
155
199
1,063
339
563
1,096
1,084
1,232
Cash Flow from Operations
-3.23
-1.80
-1.26
-1.60
-1.41
-1.99
-1.38
-1.73
-14.34
-11.03
-11.84
-50.74
-38.36
-45.63
-54.34
-26.09
-37.09
Purchase Of Property, Plant, Equipment
0.07
0.25
0.11
0.11
9.72
0.01
--
--
--
--
--
--
--
--
--
--
-- Sale Of Property, Plant, Equipment
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-1,709
-- Purchase Of Business
--
--
0.07
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Sale Of Business
-92.96
-283
-190
-315
-180
-437
-304
-426
-552
-539
-871
-2,052
-2,377
-1,396
-1,619
-1,205
-1,119
Purchase Of Investment
284
153
281
242
185
285
253
287
459
340
591
1,714
2,269
1,044
1,485
1,574
1,120
Sale Of Investment
-3.23
--
--
--
-0.50
-10.33
-18.45
-2.95
--
-62.20
-4.80
--
--
--
-1.49
-16.32
-18.00
Net Intangibles Purchase And Sale
3.23
0.00
--
-0.00
-0.00
0.00
-0.00
0.00
--
-0.00
0.00
0.00
-0.00
--
0.00
-0.00
60.16
Cash From Other Investing Activities
188
-132
89.84
-73.79
12.39
-165
-70.44
-144
-108
-272
-297
-389
-146
-397
-190
-1,382
5.81
Cash Flow from Investing
0.32
--
--
64.94
--
163
0.38
0.12
--
--
581
--
--
--
--
--
-- Issuance of Stock
--
--
--
--
--
--
--
-16.71
--
-22.37
--
--
-68.05
-131
-83.74
-541
-411
Repurchase of Stock
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Issuance of Debt
--
--
-1.06
-1.10
-0.72
-0.35
-0.04
-0.02
--
--
-4.65
-7.27
-8.83
-10.51
-13.51
-8.37
-11.37
  Payments of Debt
--
--
-1.06
-1.10
-0.72
-0.35
-0.04
-0.02
--
--
-4.65
-7.27
-8.83
-10.51
-13.51
-8.37
-11.37
Net Issuance of Debt
-1.59
-1.25
-1.06
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Cash Flow for Lease Financing
-0.00
--
1.06
-0.42
28.79
6.41
93.86
29.52
--
11.49
-27.29
19.01
12.94
27.64
7.28
2.79
-0.21
Other Financing
-1.28
-1.25
-1.06
63.42
28.07
169
94.20
12.90
34.65
-10.88
549
11.74
-63.94
-114
-89.97
-547
-423
Cash Flow from Financing
13.48
82.85
-0.36
12.30
14.62
27.45
52.60
124
49.47
206
79.91
587
1,105
1,289
1,469
2,074
827
Beginning Cash Position
-0.69
1.93
0.01
-0.50
-0.27
5.48
6.04
4.06
-15.31
2.91
2.40
-73.55
129
82.62
-76.91
146
119
  Effect of Exchange Rate Changes
75.95
-83.23
12.48
1.70
16.50
31.18
75.42
-80.23
168
-125
453
613
258
135
739
-699
934
Net Change in Cash
89.43
-0.37
12.11
14.00
31.12
58.63
128
43.44
217
81.65
533
1,200
1,364
1,424
2,207
1,375
1,761
Ending Cash Position
-3.23
-1.80
-1.26
-1.60
-1.92
-12.32
-19.83
-4.69
-14.34
-73.23
-16.64
-50.74
-38.36
-45.63
-55.83
-42.41
-69.41
Capital Expenditure
-113
46.04
-77.57
10.98
-25.61
9.34
25.79
41.69
242
82.26
182
1,013
301
517
1,040
1,042
1,163
Free Cash Flow
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Satement

Balance Sheet

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
88.71
18.01
11.38
11.87
31.12
58.63
128
43.44
217
81.65
533
1,200
1,364
1,424
2,207
1,375
1,761
  Cash And Cash Equivalents
157
276
181
255
257
376
384
512
657
854
1,112
1,458
1,580
1,789
1,970
1,569
1,650
  Marketable Securities
246
294
192
267
288
434
512
555
874
935
1,645
2,658
2,944
3,213
4,177
2,944
3,411
Cash, Cash Equivalents, Marketable Securities
19.98
11.67
12.43
24.23
25.17
17.28
25.58
138
93.31
203
448
407
513
822
734
919
1,046
  Accounts Receivable
--
--
--
--
--
--
--
--
9.30
--
--
41.16
4.72
26.19
--
14.09
--   Other Current Receivables
19.98
11.67
12.43
24.23
25.17
17.28
25.58
138
103
203
448
448
517
848
734
934
1,046
Total Receivables
--
--
--
--
--
--
--
--
--
--
--
--
--
--
2.08
0.56
--   Inventories, Raw Materials & Components
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-2.38
-2.93
--   Inventories, Inventories Adjustments
--
--
--
--
--
--
--
--
--
--
--
--
--
--
8.76
11.02
--   Inventories, Finished Goods
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-0.00
--
14.00
  Inventories, Other
--
--
--
--
--
--
--
--
--
--
--
--
--
--
8.46
8.65
14.00
Total Inventories
148
126
60.21
2.37
--
--
0.00
--
-0.00
--
0.00
-0.00
--
0.00
-0.00
0.00
-- Other Current Assets
414
432
265
293
313
452
537
693
976
1,139
2,093
3,106
3,461
4,061
4,920
3,886
4,471
Total Current Assets
--
--
--
--
--
--
--
--
--
--
22.34
179
56.48
19.14
19.90
31.81
36.00
Investments And Advances
8.25
6.72
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Buildings And Improvements
25.95
24.39
24.47
24.70
23.48
22.22
21.55
21.06
27.38
33.24
41.83
68.76
81.75
93.41
135
138
--   Machinery, Furniture, Equipment
0.19
0.67
0.30
--
--
--
0.14
0.78
10.88
0.15
7.35
2.31
7.92
33.54
5.79
14.37
--   Construction In Progress
0.00
0.00
6.68
1.70
1.78
1.57
1.41
1.36
1.73
14.55
41.23
94.21
115
135
203
228
266
  Other Gross PPE
34.39
31.79
31.45
26.40
25.26
23.79
23.10
23.20
40.00
47.95
90.40
165
204
262
344
381
266
Gross Property, Plant and Equipment
-22.80
-24.40
-25.80
-21.80
-21.07
-19.60
-18.88
-18.64
-21.72
-23.13
-28.34
-43.64
-56.02
-71.25
-100
-117
--   Accumulated Depreciation
11.59
7.39
5.65
4.60
4.20
4.19
4.22
4.56
18.28
24.82
62.07
122
148
190
244
264
266
Property, Plant and Equipment
--
--
--
--
0.47
10.21
28.22
25.74
20.05
72.00
70.46
55.87
38.67
21.01
15.00
2,076
2,103
Intangible Assets
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
354
355
  Goodwill
2.51
3.71
2.66
2.33
2.47
1.98
1.93
17.90
49.27
60.66
22.49
32.56
44.30
43.18
40.68
134
145
Other Long Term Assets
14.09
11.10
8.31
6.93
7.13
16.38
34.37
48.19
87.59
157
177
389
288
274
319
2,505
2,550
Total Long-Term Assets
428
443
273
300
320
468
572
741
1,064
1,296
2,270
3,495
3,749
4,335
5,239
6,391
7,021
Total Assets
8.63
5.84
--
--
--
--
4.69
3.15
--
--
--
23.97
--
--
--
--
--   Accounts Payable
--
--
--
--
--
--
--
8.72
--
19.61
10.94
--
--
--
8.02
239
120
  Total Tax Payable
--
--
16.95
13.99
16.11
17.22
12.28
11.68
28.44
48.41
126
150
225
247
343
486
602
  Other Current Payables
8.63
5.84
16.95
13.99
16.11
17.22
16.96
23.55
28.44
68.02
137
174
225
247
351
724
722
Accounts Payable & Accrued Expense
--
20.65
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Short-Term Debt
1.35
1.09
1.01
0.67
0.39
0.04
0.02
--
--
--
3.90
6.94
9.44
10.65
13.36
12.84
16.00
  Short-Term Capital Lease Obligation
1.35
21.74
1.01
0.67
0.39
0.04
0.02
--
--
--
3.90
6.94
9.44
10.65
13.36
12.84
16.00
Short-Term Debt & Capital Lease Obligation
--
--
151
193
151
89.84
41.41
32.28
24.28
--
--
4.30
3.96
4.75
4.90
3.35
3.00
  Current Deferred Revenue
--
--
151
193
151
89.84
41.41
32.28
24.28
--
--
4.30
3.96
4.75
4.90
3.35
3.00
DeferredTaxAndRevenue
163
209
1.85
1.87
0.16
--
2.31
2.40
--
--
--
22.15
--
-0.00
--
--
-- Other Current Liabilities
173
236
170
210
168
107
60.70
58.23
52.72
68.02
141
207
239
262
369
741
741
Total Current Liabilities
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Long-Term Debt
3.45
2.11
1.06
0.34
0.07
0.02
--
--
--
--
23.24
45.78
55.26
75.28
101
131
126
  Long-Term Capital Lease Obligation
3.45
2.11
1.06
0.34
0.07
0.02
--
--
--
--
23.24
45.78
55.26
75.28
101
131
126
Long-Term Debt & Capital Lease Obligation
0.02
0.12
0.02
0.02
0.00
--
--
--
--
--
0.01
0.02
0.02
0.02
0.02
0.03
0.03
Debt-to-Equity
--
--
--
--
--
--
--
--
--
--
--
80.49
74.14
69.09
71.27
396
397
NonCurrent Deferred Liabilities
--
--
12.60
21.54
30.12
28.77
--
--
0.39
0.31
0.15
0.17
1.98
1.58
5.20
4.19
6.00
NonCurrent Deferred Income Tax
1.55
11.61
4.02
0.47
0.27
0.23
0.21
--
0.19
0.15
0.30
0.66
0.00
0.00
-0.00
-0.00
-- Other Long-Term Liabilities
5.00
13.72
17.68
22.34
30.45
29.03
0.21
--
0.58
0.46
23.69
127
131
146
177
531
529
Total Long-Term Liabilities
178
250
188
232
198
136
60.91
58.23
53.30
68.48
164
334
370
408
546
1,272
1,270
Total Liabilities
8.65
8.01
7.84
8.92
9.58
9.30
8.72
8.54
9.86
9.35
9.75
10.91
10.05
9.50
9.80
9.21
10.00
Common Stock
-804
-790
-874
-972
-992
-821
-619
-440
-299
-30.33
319
1,175
1,525
2,131
2,824
3,286
4,032
Retained Earnings
--
--
12.64
14.24
14.29
13.73
13.84
14.56
13.23
14.09
14.69
8.93
12.33
14.11
8.91
68.36
-204
Accumulated other comprehensive income (loss)
1,035
959
938
1,016
1,090
1,130
1,108
1,099
1,287
1,235
1,762
1,966
1,831
1,772
1,850
1,757
1,913
Additional Paid-In Capital
9.99
16.01
0.00
0.00
0.00
0.00
-0.00
-0.00
0.00
0.00
--
-0.00
-0.00
0.00
0.00
0.00
-- Other Stockholders Equity
250
193
84.90
67.92
122
332
511
683
1,011
1,228
2,106
3,160
3,379
3,927
4,693
5,120
5,751
Total Stockholders Equity
250
193
84.90
67.92
122
332
511
683
1,011
1,228
2,106
3,160
3,379
3,927
4,693
5,120
5,751
Total Equity
0.58
0.44
0.31
0.23
0.38
0.71
0.89
0.92
0.95
0.95
0.93
0.90
0.90
0.91
0.90
0.80
0.82
Equity-to-Asset
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Valuation Ratios

Valuation Ratios

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
N/A
At Loss
At Loss
At Loss
97.43
69.52
72.77
61.16
57.14
44.78
43.19
33.74
58.64
35.23
32.17
12.38
13.81
PE Ratio
N/A
At Loss
At Loss
At Loss
119
69.16
72.05
63.02
46.60
50.49
44.89
30.71
73.23
37.34
29.09
14.40
15.96
PE Ratio without NRI
--
--
--
--
--
293
335
276
46.04
96.91
124
28.43
87.91
52.98
24.88
13.64
13.42
Price-to-Owner-Earnings
--
3.15
3.46
10.37
16.58
10.05
15.62
14.62
10.02
8.23
6.88
8.42
7.69
7.06
4.43
2.59
3.57
PB Ratio
--
3.15
3.46
10.37
16.66
10.37
16.53
15.20
10.22
8.74
7.12
8.57
7.78
7.09
4.45
4.36
5.64
Price-to-Tangible-Book
--
11.34
--
57.42
--
366
316
246
42.03
123
76.99
26.21
87.74
53.43
19.99
13.00
17.25
Price-to-Free-Cash-Flow
--
10.91
--
50.13
--
158
178
222
39.68
64.96
70.54
24.96
77.82
49.10
18.97
12.49
16.26
Price-to-Operating-Cash-Flow
6.39
5.03
4.88
7.33
16.47
24.62
49.02
39.98
26.66
21.80
17.43
15.88
20.60
13.24
8.50
4.51
5.78
PS Ratio
--
--
--
--
--
--
--
--
--
0.75
1.12
0.60
1.56
0.81
0.91
1.23
0.82
PEG Ratio
4.25
2.42
1.77
4.92
14.07
21.37
44.94
36.84
23.93
19.52
15.77
14.21
18.25
11.62
6.76
3.50
4.75
EV-to-Revenue
-32.33
-22.82
-3.23
-24.78
116
57.92
64.50
57.11
49.83
34.74
28.16
23.27
36.76
22.93
18.56
7.77
9.63
EV-to-EBITDA
-15.49
-17.03
-3.00
-21.42
136
60.29
67.21
59.18
53.10
36.63
29.53
24.29
39.07
24.12
19.51
8.12
10.01
EV-to-EBIT
-4.37
5.26
-1.42
33.63
-72.96
137
163
204
35.62
58.18
63.82
22.33
68.94
43.07
15.09
9.70
-- EV-to-OCF
-4.25
5.46
-1.40
38.52
-67.50
317
289
227
37.74
110
69.65
23.45
77.73
46.86
15.90
10.09
14.14
EV-to-FCF
-6.46
-5.87
-33.33
-4.67
0.74
1.66
1.49
1.69
1.88
2.73
3.39
4.12
2.56
4.15
5.13
12.32
9.99
Earnings Yield (Joel Greenblatt) %
--
--
--
-7.33
-1.75
--
--
--
--
20.75
20.78
21.25
21.30
21.40
22.79
16.92
17.22
Forward Rate of Return (Yacktman) %
--
--
--
--
--
--
--
--
15,862
431
173
144
111
83.55
51.28
27.62
33.36
Shiller PE Ratio
--
--
--
--
--
--
--
--
25.68
22.75
24.75
29.30
22.49
17.79
10.22
5.69
6.97
Cyclically Adjusted PB Ratio
--
--
--
--
--
--
--
--
57.41
50.63
52.53
57.46
47.06
35.47
19.98
10.63
12.58
Cyclically Adjusted PS Ratio
--
--
--
--
--
--
--
--
638
468
259
164
135
110
56.54
29.91
35.74
Cyclically Adjusted Price-to-FCF
--
7.89
-25.98
1.78
-1.17
0.65
0.57
0.46
2.53
1.54
1.37
4.00
1.30
2.03
5.27
8.18
-- OCF Yield %
--
7.59
-26.41
1.56
-1.26
0.28
0.32
0.42
2.39
0.81
1.26
3.81
1.16
1.87
5.00
7.86
5.95
FCF Yield %

Valuation and Quality

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
606
294
704
2,026
3,338
7,978
9,991
10,126
10,102
14,495
26,597
25,998
27,704
20,801
13,261
20,646
Market Cap
--
336
104
439
1,738
2,904
7,467
9,436
9,252
9,167
12,877
23,992
23,119
24,577
16,738
10,460
17,377
Enterprise Value
--
1.35
0.65
1.40
3.91
5.86
13.40
16.58
16.58
16.48
22.33
40.66
39.56
42.38
31.84
20.87
33.72
Month End Stock Price
0.15
0.10
0.01
0.07
0.17
0.52
0.76
0.82
1.34
1.41
2.28
3.55
3.92
4.29
5.56
2.63
3.48
Net Cash per Share
0.52
0.40
0.17
0.12
0.22
0.55
0.80
1.05
1.51
1.75
2.97
4.24
4.70
5.59
6.70
4.11
5.20
Net Current Asset Value
0.18
0.12
0.03
0.10
0.21
0.55
0.79
1.00
1.46
1.66
2.80
4.02
4.50
5.23
6.41
3.72
4.76
Net-Net Working Capital
--
--
--
--
-0.26
0.12
0.65
0.80
2.51
3.04
4.67
10.00
10.68
12.78
17.09
20.69
27.30
Intrinsic Value: Projected FCF
--
--
--
--
--
--
--
--
--
13.91
27.22
59.09
43.67
78.15
89.70
104
116
Median PS Value
--
--
--
--
--
--
--
--
--
9.25
13.49
32.00
10.30
30.10
27.56
16.63
27.62
Peter Lynch Fair Value
--
--
--
--
0.42
1.05
1.84
2.55
3.58
3.70
5.89
11.83
7.90
12.28
13.22
12.53
16.29
Graham Number
--
--
--
-0.33
-0.53
0.30
0.82
1.43
2.79
3.33
5.12
8.16
8.76
10.96
14.46
14.79
19.05
Earnings Power Value (EPV)
0.84
-0.50
-3.24
-2.35
2.83
14.04
78.95
105
114
89.39
54.46
50.35
45.08
43.28
25.45
8.70
12.49
Altman Z-Score
4.00
6.00
3.00
5.00
5.00
6.00
5.00
6.00
6.00
5.00
4.00
6.00
2.00
6.00
4.00
5.00
6.00
Piotroski F-Score
--
74.52
-3.03
-4.57
-1.47
-1.42
-0.78
1.26
-2.65
-1.29
-1.60
-2.23
-2.60
-1.81
-3.08
6.95
-2.47
Beneish M-Score
0.01
-0.18
-0.24
-0.72
-0.55
-0.32
-0.00
0.22
0.19
0.28
0.38
0.25
0.14
0.21
0.15
0.44
0.38
Scaled Net Operating Assets
-63.71
6.00
-43.08
-8.37
10.01
41.14
23.91
35.77
2.77
26.42
18.64
3.20
6.86
14.28
-4.95
21.79
2.95
Sloan Ratio %
2.39
1.83
1.55
1.40
1.87
4.22
8.85
11.90
18.52
16.74
14.88
15.00
14.50
15.48
13.34
5.25
6.03
Current Ratio
2.39
1.83
1.55
1.40
1.87
4.22
8.85
11.90
18.52
16.74
14.88
15.00
14.50
15.48
13.32
5.24
6.01
Quick Ratio
1.42
1.25
1.13
1.27
1.72
4.06
8.43
9.53
16.58
13.75
11.70
12.83
12.33
12.25
11.33
3.98
4.60
Cash Ratio
--
--
--
--
20.81
65.40
6,293
4,966
673
No Debt
377
631
227
161
76.01
58.36
54.04
Interest Coverage
--
1.35
1.35
1.42
4.67
6.00
13.94
19.37
23.48
21.68
24.14
40.76
48.72
47.06
43.22
32.77
33.89
Highest Stock Price
--
1.17
0.65
0.65
1.40
3.40
5.78
9.70
16.29
12.12
14.53
17.15
30.92
26.83
27.94
20.02
17.24
Lowest Stock Price
-0.59
-0.01
--
-12.03
-2.88
-10.07
-4.50
-1.21
-1.39
-0.38
-5.86
-0.77
-0.47
0.53
0.06
2.74
3.06
Shares Buyback Ratio %
--
--
--
-9.22
--
-4.88
--
0.17
--
0.22
-4.01
--
0.26
0.47
0.40
4.08
2.02
Buyback Yield %
-13.45
-7.97
-41.13
37.50
26.74
2.53
12.35
52.38
47.60
21.66
69.21
101
-23.50
63.04
17.33
25.22
19.71
YoY Rev. per Sh. Growth
-7.18
70.44
-81.25
18.97
121
115
114
47.83
5.15
27.27
40.11
134
-42.88
74.34
-17.58
72.76
109
YoY EPS Growth
84.72
24.24
-200
50.67
178
207
113
41.05
10.07
42.37
68.57
119
-37.83
66.36
-15.61
54.81
66.11
YoY EBITDA Growth
--
--
--
--
--
--
--
--
--
67.25
40.01
50.82
46.95
45.92
32.09
11.71
19.40
5-Year EBITDA Growth Rate
449
449
449
460
510
563
585
599
608
613
630
652
654
654
653
642
616
Shares Outstanding (Basic Average)
449
449
449
503
518
570
595
603
611
613
649
654
657
654
653
635
616
Shares Outstanding (EOP)
--
--
--
--
1.32
0.86
1.07
1.00
0.78
0.54
-0.07
0.59
0.71
1.05
1.00
0.88
0.82
Beta
03/19/10
03/16/11
03/07/12
03/07/13
03/04/14
03/02/15
02/17/16
02/22/17
02/22/18
02/20/19
03/30/20
03/29/21
02/16/22
02/22/23
02/14/24
02/12/25
  Filing Date
03/16/11
03/07/12
03/07/13
03/04/14
03/02/15
02/17/16
02/22/17
02/22/18
03/30/20
03/29/21
02/16/22
02/22/23
02/14/24
02/12/25
02/12/25
02/12/25
  Restated Filing Date
02/20/19
02/19/20
02/23/21
02/16/22
02/14/24
02/12/25
  Earnings Release Date
565
189
179
180
180
180
180
180
180
180
548
781
1,212
1,660
2,204
2,682
2,681
Number of Employees
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Business & Geographic Segmentation

Business Segments

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
--
--
--
--
--
--
--
--
--
--
--
--
--
1,673
1,942
1,744
DARZALEX
--
--
--
--
--
--
--
--
--
--
--
--
--
--
222
310
320
Kesimpta
--
--
--
--
--
--
--
--
--
--
--
--
--
--
62.51
243
280
Net product sales
--
--
--
--
--
--
--
--
--
--
--
--
--
--
175
140
66.00
Milestone revenue
--
--
--
--
--
--
--
--
--
--
--
--
--
--
128
139
43.00
Reimbursement revenue
--
--
--
--
--
--
--
--
--
--
--
--
--
--
105
103
75.00
TEPEZZA
--
--
--
--
--
--
--
--
--
--
--
--
--
--
35.93
65.71
80.00
Other
--
--
--
--
--
--
--
--
--
--
--
--
--
--
45.58
60.41
54.00
Collaboration revenue
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.28
-- License revenue
--
--
--
--
--
--
--
--
--
--
804
1,671
1,291
2,101
--
--
-- Single segment

Geographic Segments

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
--
--
--
--
--
--
257
381
463
804
1,671
1,291
2,101
2,383
2,760
-- Denmark
--
--
--
--
--
--
--
--
--
--
--
--
--
--
56.42
126
-- United States
--
--
--
--
--
--
--
--
--
--
--
--
--
--
6.09
117
-- Japan
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Dec 26, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Explanation

1. Predictability Rank

GuruFocus Predictability Rank is a proprietary ranking of the consistency of a business. We rank the predictability of companies based on the consistency of their revenue per share and EBITDA (earnings before interest, tax, depreciation and amortization) per share over the past 10 fiscal years. Our study found that there is a strong correlation between the stock performance and the predictability of a business. Over the long term, companies with higher predictability also have better stock performance.

The rank is from 1-star to 5-star, with 5-star as the best.

2. Financial Strength

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

  1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
  2. Debt to revenue ratio. The lower, the better.
  3. Altman Z-Score.

The rank is from 1 to 10, with 10 as the highest.

A Financial Strength rank of 8 or above indicates good financial strength; between 4-7 indicates fair financial strength; 3 or below means poor financial strength.

3. Profitability Rank

GuruFocus Profitability Rank indicates how profitable a company is and how likely it is that the company's business will stay that way. It is based on these factors:

  1. Operating Margin %.
  2. Piotroski F-Score.
  3. Trend of the Operating Margin percentage (five-year average). A company with an uptrend in profit margin will have a higher rank.
  4. Consistency of the profitability.
  5. Predictability Rank.

The rank is from 1 to 10, with 10 as the highest.

A Profitability Rank of 8 or above indicates good profitability; between 4-7 indicates fair profitability; 3 or below means poor profitability.

4. Peter Lynch Chart

In Peter Lynch's excellent book, "One Up on Wall Street," he used many charts to illustrate the valuation of stocks. “A quick way to tell if a stock is overpriced is to compare the price line to the earnings line. If you bought familiar growth companies – such as Shoney’s, The Limited, or Marriott – when the stock price fell well below the earnings line, and sold them when the stock price rose dramatically above it, the chances are you’d do pretty well.”

The original Peter Lynch Chart does have limitations due to the right side price scale is pre-set at 15 times the earnings scale on the left side. When the stock price and earnings line coincide, the price-to-earnings ratio is always 15 times. Instead of using the fixed PE Ratio of 15, our approach is using 15-year historical median PE without NRI Ratio for each stock.

The Peter Lynch Chart with earnings line at median PE without NRI ratio works well for the companies with steady growth and earnings trends, or the stalwarts, as coined by Lynch. These companies tend to be found in sectors such as consumer staples, healthcare, and utilities, where the consumption of the product or service is relatively independent of economic conditions. It does not work well with the sectors that are cyclical: industrials, chemicals, durable goods, and so forth.

5. GF Value

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

  1. Possible Value Trap, Think Twice
  2. Significantly Overvalued
  3. Modestly Overvalued
  4. Fairly Valued
  5. Modestly Undervalued
  6. Significantly Undervalued
There is only a sufficient margin of safety when the stock is undervalued.

Disclaimer

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.